Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Jornay PM (methylphenidate hydrochloride) is an FDA-approved extended-release capsule used to treat Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and older. What makes Jornay PM unique among ADHD stimulants is its evening dosing — patients take it between 6:30 PM and 9:30 PM, and the medication's delayed-release technology ensures that therapeutic levels are reached by the following morning and sustained throughout the day. This is especially helpful for patients who struggle with early-morning ADHD symptoms, such as difficulty getting ready for school or work.
Jornay PM contains methylphenidate, which works by blocking the reuptake of norepinephrine and dopamine into presynaptic neurons. This increases the concentration of these neurotransmitters in the brain, improving focus, attention, and impulse control. Jornay PM uses a proprietary delayed-release/extended-release (DR/ER) bead technology — less than 5% of the drug is absorbed in the first 10 hours after taking it in the evening, with peak therapeutic levels building by the next morning and lasting throughout the day.
Jornay PM earns a moderate findability score of 55. It is not on the FDA's official drug shortage list, and the manufacturer (Collegium Pharmaceutical) continues to produce it. However, because Jornay PM is a brand-only specialty medication with no generic equivalent, most retail pharmacies do not routinely stock it. Patients often need to call multiple pharmacies, try independent or specialty pharmacies, or request a special order. The broader ADHD stimulant shortage has also created additional competition for available supply. Using a tool like Medfinder can significantly speed up the search process.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Jornay PM is most commonly prescribed by psychiatrists, child and adolescent psychiatrists, and pediatricians who specialize in ADHD treatment. Primary care physicians and family medicine doctors may also prescribe it, particularly for adult patients. Because Jornay PM is a Schedule II controlled substance, all prescribers must hold a valid DEA registration. Some neurologists also prescribe it for patients with ADHD.
Yes. Jornay PM is classified as a Schedule II (CII) controlled substance by the DEA. This means it has a high potential for abuse and dependence. Prescriptions cannot be called in to pharmacies in most states — they must be sent electronically or provided as a written prescription. Refills are not allowed on Schedule II medications; a new prescription is required each time. The FDA's boxed warning notes that CNS stimulants including Jornay PM carry a risk of substance use disorder, including addiction, and that misuse can result in overdose and death.
Jornay PM fills a unique niche in ADHD treatment as the only stimulant designed for evening dosing with next-morning onset. For patients who struggle with early-morning symptoms or can't tolerate the timing of traditional morning stimulants, it can be a game-changer. However, its brand-only status, higher cost, and limited pharmacy stocking mean that finding and affording Jornay PM takes extra effort. Use Medfinder to check real-time availability, explore the manufacturer savings card at jornaypm.com, and work with your prescriber to navigate insurance requirements. No generic is expected until 2032, so these strategies will remain important for the foreseeable future.
%2C%20Color%3DOriginal.png)
